Loading
A drug aimed at a mutation present in every tumour cell works differently from one aimed at a mutation in only some cells. Test reports should say which is which.
Tumour sequencing reports list alterations without their cancer cell fraction. Adding a clonality estimate (truncal, subclonal with estimated fraction, indeterminate) is computationally routine from purity- and copy-number-adjusted VAFs. Trials could then stratify by clonality and drug labels could state that benefit was shown for clonal alterations.
Shares Foundation Medicine (Roche), Tempus AI, Guardant Health, Next-generation sequencing (NGS).
Shares Foundation Medicine (Roche), Tempus AI, Next-generation sequencing (NGS), Biomarkers are not validated or standardised.
Shares Foundation Medicine (Roche), Guardant Health, Comprehensive genomic profiling.
Shares Foundation Medicine (Roche), Tempus AI, Guardant Health, Next-generation sequencing (NGS).
Shares Tumour heterogeneity and clonal evolution, Biomarkers are not validated or standardised, Comprehensive genomic profiling.
Shares Variant allele frequency (VAF), Guardant Health, Biomarkers are not validated or standardised.
Shares Variant allele frequency (VAF), Guardant Health, Biomarkers are not validated or standardised.